Home/News Feed/Engitix partners with GSK to develop new treatments targeting liver fibrosis regression.

$51.09

+$2.38 +4.90%

Engitix partners with GSK to develop new treatments targeting liver fibrosis regression.

Company Fundamentals

08 Jun 2026, 13:16 WIB

GlobeNewsWire

View Source

Bullish

Engitix partners with GSK to develop new treatments targeting liver fibrosis regression.

Engitix Ltd. has entered a strategic collaboration with GSK to identify and validate new therapeutic targets aimed at reversing liver fibrosis. The partnership leverages Engitix’s human extracellular matrix (ECM) platform and multi-omics data alongside GSK’s drug development expertise. Engitix may receive up to £44.5 million upfront and additional milestone payments, while GSK will lead further research and commercialization of any discovered targets. This collaboration focuses on fibrosis regression mechanisms, potentially transforming treatment options for liver fibrosis patients.

More News (GSK)

Alamar Biosciences and GSK launch large-scale proteomic study to improve disease detection and treatment.

Alamar Biosciences has partnered with GSK to use its NULISA platform for a large-scale proteomic study analyzing over 60,000 serum samples. The study aims to identify protein signatures linked to disease progression, biological subtypes, and treatmen...

Market News

Bullish

1 day ago

Engitix partners with GSK to develop new treatments targeting liver fibrosis regression.

More News (GSK)

Alamar Biosciences and GSK launch large-scale proteomic study to improve disease detection and treatment.

Invest & Trade with#1 Award-Winning Investment Super App

Invest & Trade with
#1 Award-Winning Investment Super App